Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma: A Phase II Trial of the Sarah Cannon Research Institute
Ian W. Flinn(Tennessee Oncology), Jesús G. Berdeja(Tennessee Oncology), Gerald Miletello(Hematology\Oncology Clinic), Andrew Lipman(Sarah Cannon), Steven W. Papish(Reproductive Medicine Associates of New Jersey), Daniel Cuevas, Dana S. Thompson(Sarah Cannon), Ralph V. Boccia(Center for Cancer and Blood Disorders), Douglas B. Flora(Oncology Hematology Care)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k